Houston, Texas 77030


Purpose:

The goal of this clinical research study is to learn if positron emission tomography/magnetic resonance imaging (PET/MRI), positron emission tomography/computed tomography (PET/CT) and whole body magnetic resonance imaging (MRI) can be used to detect extramedullary myeloid leukemia (EML). EML is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. This is an investigational study. The PET/MRI and PET/CT scans on this study are performed using FDA-approved and commercially available methods. Using these scans to detect EML is considered investigational. Up to 55 participants will be enrolled on this study. All will take part at MD Anderson..


Study summary:

If you choose to take part in this study, you will have a PET/MRI and PET/CT scan before you start your regular treatment. When you arrive at the clinic for your PET/MRI-PET/CT scans, you will receive a "radioisotope" and a "contrast" solutions by vein to make the images more accurate. If you feel very nervous, the doctor may give you medication to help calm you down. You will have the PET/MRI scan, for which you will have to lie on a table in the scanner for about an hour. In a different room, you have a PET/CT scan, for which you will have to lie on a table in the scanner for about 30 minutes. You and your regular doctor will be told if anything unusual is found in your scans, and the information will be put in your medical record. Information will also be collected from your medical record for at least 1 year after you complete the scans.


Criteria:

Inclusion Criteria: 1. Patients with newly diagnosed AML or acute promyelocytic leukemia (APL) 2. Women of child bearing potential with negative pregnancy test documented Exclusion Criteria: 1. Patients with contraindications to MR 2. Patients with a creatinine clearance less than 60 3. Patients with a known allergy to MR contrast agents 4. Uncontrollable claustrophobia 5. Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter. 6. Patients with secondary or relapsed AML or APL should be excluded. 7. Patients with known extramedullary leukemia 8. Positive pregnancy test 9. Younger than 18 years 10. Greater than 400 pounds in weight 11. Patients with uncontrolled diabetes


NCT ID:

NCT02390635


Primary Contact:

Principal Investigator
Vikas Kundra, MD, PHD
M.D. Anderson Cancer Center

Vikas Kundra, MD, PHD
Phone: 713-745-2702


Backup Contact:

N/A


Location Contact:

Houston, Texas 77030
United States



There is no listed contact information for this specific location.

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.